A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2009 |
| End Date: | February 2011 |
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients
treated with this strategy consisting of initial therapy with pertuzumab as a single agent
and then addition of erlotinib for those who have stable disease or progressive disease at
three months (Simon design).
We found this trial at
1
site
Stanford university Hospital and Clinics Throughout our history, we have pioneered medical advances that save...
Click here to add this to my saved trials
